Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resistance and acquired resistance to the drugs are maj...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, Morita, Kiyomi, DiNardo, Courtney D., Furudate, Ken, Tanaka, Tomoyuki, Yan, Yuanqing, Patel, Keyur P., MacBeth, Kyle J., Wu, Bin, Liu, Guowen, Frattini, Mark, Matthews, Jairo A., Little, Latasha D., Gumbs, Curtis, Song, Xingzhi, Zhang, Jianhua, Thompson, Erika J., Kadia, Tapan M., Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Bhalla, Kapil N., Konopleva, Marina, Kantarjian, Hagop M., Andrew Futreal, P., Takahashi, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110775/
https://www.ncbi.nlm.nih.gov/pubmed/33972549
http://dx.doi.org/10.1038/s41467-021-22874-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110775/
https://www.ncbi.nlm.nih.gov/pubmed/33972549
http://dx.doi.org/10.1038/s41467-021-22874-x

Ejemplares similares